- $488.07m
- $320.48m
- $10.84m
Brief: Glycomimetics Reports Highlights And Financial Results For Fourth Quarter And Full Year 2021
GlycoMimetics Inc expected to post a loss of 34 cents a share - Earnings Preview
GlycoMimetics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: GlycoMimetics Inc Says NCI-Sponsored Trial Of Uproleselan In Older, Newly Diagnosed AML Patients Fit For Intensive Chemotherapy Completes Enrollment Of Phase 2 Portion Ahead Of Schedule
Brief: Apollomics Inc. Doses First Patient In Phase 3 Clinical Trial In China Of Glycomimetics’ Uproleselan For The Treatment Of Aml
Brief: GlycoMimetics Appoints Regulatory Veteran Lisa Deluca As Vice President, Regulatory Affairs
Brief: Glycomimetics Completes Enrollment Of Phase 3 Registration Trial Evaluating Uproleselan In Acute Myeloid Leukemia (Aml)
Brief: GlycoMimetics GMI-1359 Data Selected For Presentation At ASH Annual Meeting And Exposition
GlycoMimetics Inc reports results for the quarter ended in September - Earnings Summary
GlycoMimetics Inc expected to post a loss of 32 cents a share - Earnings Preview
GlycoMimetics rises after encouraging data from leukemia drug trial
Brief: Data For GlycoMimetics’ Lead Investigational Drug Uproleselan Published
GlycoMimetics Inc reports results for the quarter ended in June - Earnings Summary
Brief: GlycoMimetics Names Harout Semerjian as New CEO
GlycoMimetics Inc expected to post a loss of 31 cents a share - Earnings Preview
GlycoMimetics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: GlycoMimetics Launches Trial To Evaluate Co's Drug Candidate In AML Patients
Brief: GlycoMimetics Announces Initiation Of Clinical Trial Evaluating Uproleselan In Combination With Venetoclax And Azacitidine
Brief: Glycomimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan For Prevention Of Gastro-Intestinal Toxicity In Autologous Hematopoietic Cell Transplantation